[
  {
    "ts": "2025-12-10T09:30:00+00:00",
    "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
    "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
    "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
    "source": "South China Morning Post",
    "provider": "yfinance",
    "raw": {
      "id": "e5809500-2c36-38a7-8c06-27c432a47945",
      "content": {
        "id": "e5809500-2c36-38a7-8c06-27c432a47945",
        "contentType": "STORY",
        "title": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
        "description": "",
        "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
        "pubDate": "2025-12-10T09:30:00Z",
        "displayTime": "2025-12-10T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c",
          "originalWidth": 1999,
          "originalHeight": 1445,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NrMYkjybZfgvsVPgy08KfA--~B/aD0xNDQ1O3c9MTk5OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 1999,
              "height": 1445,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vF.Bc5MyIqpbyFQCk.k5zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "South China Morning Post",
          "url": "https://www.scmp.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T11:26:00+00:00",
    "headline": "The Fed’s Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today.",
    "summary": "What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.",
    "url": "https://www.barrons.com/articles/fed-rate-cut-stock-market-things-to-know-today-d80aa5d3?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "06666fad-2e56-3324-be7c-ace6c6d074a9",
      "content": {
        "id": "06666fad-2e56-3324-be7c-ace6c6d074a9",
        "contentType": "STORY",
        "title": "The Fed’s Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today.",
        "description": "",
        "summary": "What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.",
        "pubDate": "2025-12-10T11:26:00Z",
        "displayTime": "2025-12-10T11:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/06666fad-2e56-3324-be7c-ace6c6d074a9/the-fed%E2%80%99s-divided-on-rates-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/02b5b2b4fd9376e9e96d8ee4291b510c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n05p7rYmial99bxdcEaw7g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/02b5b2b4fd9376e9e96d8ee4291b510c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7RTS9LgiSde4..JWXbEW1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/02b5b2b4fd9376e9e96d8ee4291b510c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/fed-rate-cut-stock-market-things-to-know-today-d80aa5d3?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GEV"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "WBD"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T13:15:00+00:00",
    "headline": "TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer",
    "summary": "NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo",
    "url": "https://finance.yahoo.com/news/tukysa-added-first-line-maintenance-131500580.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e868b1e8-b98c-3031-b176-f21fb2372685",
      "content": {
        "id": "e868b1e8-b98c-3031-b176-f21fb2372685",
        "contentType": "STORY",
        "title": "TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer",
        "description": "",
        "summary": "NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo",
        "pubDate": "2025-12-10T13:15:00Z",
        "displayTime": "2025-12-10T13:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/13a19b32d6bd0716178e832b10681bcc",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wMiRvg4mzBbef_Ze5DUj2A--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13a19b32d6bd0716178e832b10681bcc.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzI_sMwefaJje78Qy5Xo.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13a19b32d6bd0716178e832b10681bcc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tukysa-added-first-line-maintenance-131500580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tukysa-added-first-line-maintenance-131500580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T12:43:00+00:00",
    "headline": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
    "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
    "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "21ccecca-5adc-31eb-bc07-c7accb75b166",
      "content": {
        "id": "21ccecca-5adc-31eb-bc07-c7accb75b166",
        "contentType": "STORY",
        "title": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence",
        "description": "",
        "summary": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.",
        "pubDate": "2025-12-10T12:43:00Z",
        "displayTime": "2025-12-10T12:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-buys-oral-glp-1-124300716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T12:31:00+00:00",
    "headline": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
    "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
    "url": "https://finance.yahoo.com/news/jnj-vs-pfe-blue-chip-123100822.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8b59f587-2747-3b59-8772-5695fe2d24b7",
      "content": {
        "id": "8b59f587-2747-3b59-8772-5695fe2d24b7",
        "contentType": "STORY",
        "title": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?",
        "description": "",
        "summary": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.",
        "pubDate": "2025-12-10T12:31:00Z",
        "displayTime": "2025-12-10T12:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O2fLjSeGpHAp4pnNFR6egw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qPY9mhd4gwuyP0ATgGKKxQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jnj-vs-pfe-blue-chip-123100822.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jnj-vs-pfe-blue-chip-123100822.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T16:28:43+00:00",
    "headline": "Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-results-162843521.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "41481f1e-293e-378f-8048-46301f9402bc",
      "content": {
        "id": "41481f1e-293e-378f-8048-46301f9402bc",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]",
        "pubDate": "2025-12-10T16:28:43Z",
        "displayTime": "2025-12-10T16:28:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-results-162843521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-announces-results-162843521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T16:47:51+00:00",
    "headline": "This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
    "summary": "Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
    "url": "https://247wallst.com/investing/2025/12/10/this-invesco-etf-pays-a-4-71-yield-with-50-low-volatility-dividend-stocks-3x-the-sp-500/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "09c04397-cab4-3c8d-a2e7-38cd27a520e4",
      "content": {
        "id": "09c04397-cab4-3c8d-a2e7-38cd27a520e4",
        "contentType": "STORY",
        "title": "This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
        "description": "",
        "summary": "Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)",
        "pubDate": "2025-12-10T16:47:51Z",
        "displayTime": "2025-12-10T16:47:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/d00aaf11934d90ac004de8c743155bc3",
          "originalWidth": 1376,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RihBwzwaaPDGnqgYiV55aw--~B/aD03Njg7dz0xMzc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/d00aaf11934d90ac004de8c743155bc3.cf.webp",
              "width": 1376,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4trQ4KjEmGKFYY_2m4cHpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/d00aaf11934d90ac004de8c743155bc3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/10/this-invesco-etf-pays-a-4-71-yield-with-50-low-volatility-dividend-stocks-3x-the-sp-500/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/invesco-etf-pays-4-71-164751597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MO"
            },
            {
              "symbol": "O"
            },
            {
              "symbol": "DOC"
            },
            {
              "symbol": "D"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VZ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T20:58:17+00:00",
    "headline": "Sector Update: Health Care Stocks Climb Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index adding 1.6% and the",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-climb-205817241.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "5d886b00-91ab-38ce-badb-3cfa98b5e8b3",
      "content": {
        "id": "5d886b00-91ab-38ce-badb-3cfa98b5e8b3",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Climb Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index adding 1.6% and the",
        "pubDate": "2025-12-10T20:58:17Z",
        "displayTime": "2025-12-10T20:58:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-climb-205817241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-climb-205817241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CNTA"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]